SBI Securities Co. Ltd. acquired a new stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 2,905 shares of the company’s stock, valued at approximately $29,000.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. KBC Group NV acquired a new stake in shares of Ginkgo Bioworks during the 4th quarter worth approximately $31,000. Bank of New York Mellon Corp grew its position in shares of Ginkgo Bioworks by 48.2% during the 4th quarter. Bank of New York Mellon Corp now owns 23,061 shares of the company’s stock worth $226,000 after buying an additional 7,503 shares during the period. Palumbo Wealth Management LLC acquired a new stake in shares of Ginkgo Bioworks during the 4th quarter worth approximately $144,000. Y Intercept Hong Kong Ltd acquired a new position in Ginkgo Bioworks during the fourth quarter valued at approximately $154,000. Finally, SVB Wealth LLC acquired a new position in Ginkgo Bioworks during the fourth quarter valued at approximately $171,000. Institutional investors and hedge funds own 78.63% of the company’s stock.
Ginkgo Bioworks Stock Performance
Shares of NYSE DNA opened at $6.65 on Thursday. The stock has a market cap of $385.64 million, a P/E ratio of -0.51 and a beta of 1.23. The firm has a 50 day moving average price of $11.21 and a 200 day moving average price of $9.21. Ginkgo Bioworks Holdings, Inc. has a 52-week low of $5.26 and a 52-week high of $49.20.
Ginkgo Bioworks Profile
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Read More
- Five stocks we like better than Ginkgo Bioworks
- Investing in Travel Stocks Benefits
- Ramaco Resources Pins Hopes on Coal’s Untapped Potential
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- Stock Market Upgrades: What Are They?
- Why Energy Transfer Belongs on Your Watchlist
Want to see what other hedge funds are holding DNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Free Report).
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
